Management of Interferon-β1b (Betaseron) Failures in Multiple Sclerosis with Interferon-αn3 (Alferon N)

  • W. A. Sheremata
  • A. Minagar
Part of the Topics in Neuroscience book series (TOPNEURO)


The introduction of interferon-β1b (IFN-β1b, Betaseron) in 1993 heralded a new era in the management of multiple sclerosis (MS). A modest overall reduction of exacerbations of 33.8% was enhanced by a 47% reduction for “moderately severe and severe exacerbations”, as defined in the protocol [1]. Adverse experience with IFN-β1b, however, was encountered in the majority of trial participants, as well as in the clinical setting [1, 2].


Multiple Sclerosis Multiple Sclerosis Patient Hairy Cell Leukemia Adverse Experience Cutaneous Ulceration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661CrossRefGoogle Scholar
  2. 2.
    Report of the Quality Standards Subcommittee of the AAN (1994) Neurology 44:1537–1540CrossRefGoogle Scholar
  3. 3.
    Sheremata WA, Taylor A, Elgart GW (1995) Severe necrotizing cutaneous lesions complicating interferon-beta-lb: clinical features and biopsy results. N Engl J Med 332:23CrossRefGoogle Scholar
  4. 4.
    Elgart GW, Sheremata WA, Ahn YS (1997) Cutaneous reactions to recombinant interferon-beta-lb: the clinical and histologic spectrum. J Am Acad Dermatol 37:553–558PubMedCrossRefGoogle Scholar
  5. 5.
    Paty DW, Hartung HP, Ebers GC et al (1999) Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur Neurol 6 [Suppl 1]:S1–S35Google Scholar
  6. 6.
    Di Paola M, Ogin E, Smith Y et al (1992) Interferon-a subtypes in natural human leukocyte interferon (interferonα-n3). J Interferon Res 12:5318Google Scholar
  7. 7.
    Squillacote D, Martinez M, Sheremata WA (1996) Natural alpha interferon in multiple sclerosis: preliminary results and follow-up. J Int Med Res 24:246–257PubMedGoogle Scholar
  8. 8.
    Sheremata W, Minagar A, Whiteman M, Onufer J (2001) Interferon-alfa-n3 (Alferon N) reduces gadolinium enhancing brain lesions in multiple sclerosis. J Neurosci 187 [Suppl 1] S454Google Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • W. A. Sheremata
  • A. Minagar

There are no affiliations available

Personalised recommendations